We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

This little-known artificial intelligence growth stock is backed by chipmaker Nvidia and recently jumped nearly 24% in a ...

We recently compiled a list of the 5 Stocks Jensen Huang’s Company is Betting On. In this article, we are going to take a ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) soared 40 percent week-on-week, with the company also experiencing a ...

We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...

The Japanese investment holding company SoftBank Group ( OTCPK:SFTBY) purchased two new stakes: 20.45M shares in Pacific Biosciences of California ( PACB ), and 14.66M shares in Recursion ...

Recursion Pharmaceuticals (RXRX), Crispr Therapeutics (CRSP), iShares MSCI India (INDA), Faraday Future Intelligent Electric (FFIE), Bilibili (BILI), Procter & Gamble (PG), UP Fintech Holding Ltd ...

The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $8.50, reflecting a +1.92% shift from the previouse trading day's closing. The stock outperformed the S&P 500, ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.